tbuckley/cabot-search huggingface dataset:
AB0045 MESENCHYMAL STEM CELLS INHIBIT THE ACTIVATED COMPLEMENT C5 BY CLUSTERIN IN LUPUS NEPHRITIS
Authors: Haijun Ma, Chang Liu, Ruihai Feng, Lingyun Sun
Journal: Annals of the Rheumatic Diseases (2019)

<h3>Background:</h3> Dysregulation of clusterin (CLU) and over-activated complement C5 were involved in the development and progression of lupus nephritis (LN). Allogeneic mesenchymal stem cells (MSCs) transplantation has achieved good clinical efficacy for refractory LN, however, the exact mechanisms remain to be elucidated. <h3>Objectives:</h3> To investigate the clinical effect of MSCs on SLE model mice (B6.lpr), and explore the mechanisms of MSCs inhibiting the activated complement C5<i> in vivo</i> and <i>in vitro</i>. <h3>Methods:</h3> 26-week-old female B6.lpr mice were randomly allocated in three groups, which were given the following treatments, CTX (200mg/kg), MSCs (1 x 10<sup>6</sup>), and an equal volume of PBS. 24 hours urine and peripheral blood were collected periodically. All mice were sacrificed at 40 weeks of age. Urine protein to creatinine ratio and plasma creatinine were quantified to evaluate renal disease. Levels of C3, soluble C5b-9 (SC5b-9), CLU, and anti-dsDNA antibody were determined in the plasma by ELISA. Histopathological evaluation of renal lesions was undertaken by HE, PAS, PASM and Masson staining under light microscopy. Podocyte foot processes were assayed by the transmission electron microscopy. Accumulation of immunocomplexes (IC), C3, C5b-9, and CLU were detected in renal specimens by immunofluorescence or immunohistochemistry. Expressions of CLU in MSCs were detected by real-time PCR and ELISA. MSCs-derived CLU was purified and functional analysis was performed accordingly. <h3>Results:</h3> Compared to the control mice, both proteinuria and plasma creatinine were significantly improved in each treatment group. Plasma C3 was significantly elevated in mice of MSCs and CTX groups. There were decline trends in plasma levels of anti-dsDNA and SC5b-9 in treated mice when compared to the control mice. Notably, plasma CLU was only significantly elevated in MSCs treated mice. Pathological analysis showed that the proliferation of glomerular cells and foot process fusion were significantly alleviated in MSCs treated mice. Immunofluorescence and immunohistochemistry showed that depositions of IC, C1q, C3 and C5b-9 were significantly decreased in the MSCs group, although the expression of CLU was obviously increased in these mice. Mechanistically, interferon-α promoted the secretion of functional CLU by MSCs <i>in vitro</i>. <h3>Conclusion:</h3> Allogeneic MSCs transplantation can effectively improve the clinical outcome of lupus mice. Possible mechanisms of MSCs might be related to inhibit the activated C5 via clusterin, which would be a potential treatment target in the future. <h3>Reference</h3> [1] Harris CL, et al. Mol Immunol. 2018 <h3>Disclosure of Interests:</h3> None declared
TCT CONNECT-65 Cangrelor Use Patterns and Transition to Oral P2Y12 Inhibitors Among Patients With Myocardial Infarction: Early Results From the CAMEO (Cangrelor in Acute Myocardial Infarction: Effectiveness and Outcomes) Registry
Authors: Jennifer Rymer, Deepak Bhatt, Dominick Angiolillo, Miguel Diaz, Laura Edwards, Khalid Salahuddin, Carmen Dell'Anna
Journal: Journal of the American College of Cardiology (2020)
AB0149 Studying of thew efficiency of the synvisk in osteoartrosis
Authors: L Groppa, M Moshneaga
Journal: Annals of the Rheumatic Diseases (2001)

<h3>Background</h3> At present for improvement of life quality in patients with osteoartrosis is necessary to solve some problems: precluding of development of degenerative process in cartilage of affected joint, relieving of pain and improvement of the function of the joint. For these aims we studied the efficiency of the chondroprotective drug Synvisk by Boenhringer Ingelheim in 25 patients with arthrosis of the knee in medium age of 61,2 ± 1,7 years, 16 women and 8 men, with duration of the disease 5,8 ± 0,9 years. Conform X-ray data the distribution of the patients by stages of the disease was as follow: I grade ? 20%, II grade ? 64%, and III grade ? 16%. In experimental group the drug was administered intraarticular by blind method in dose of 2,0 ml one time in a week, 3 injections for the course, which were repeated after 6 and 12 months. The control group was matched by gender, duration of disease and X-ray date; in this group was administrated placebo conforming same scheme. Evaluation of the effectiveness and tolerability of compared drugs was carried out in evolution of clinical (pain, functional index by Lesquesne, volume of movement on affected joints), X-ray parameters and functional methods (ultrasonography, scintigraphy with Te99m. In the basic group were mentioned decreasing of the pain intensity and improvement of the joint functions after single injection in one third of the patients, while in control groups similar cases were absent. After 3 courses of the treatment in the basic group the effects were obtained in 86,7% of the patients, including 33,3% very good effect, in 53,4% moderate effect and only in 13,3% the effects were absent. In control group there were no effect in 80% of the patients, and in 20% of the patients there were mentioned moderate effects; good effects were are not observed. Thus, a presented result suggests that administration of Synvisk lead to significant improvement of the life quality in the patients with arthrosis of the knee. <h3>Objectives &nbsp;Methods &nbsp;Results &nbsp;Conclusion</h3>
TCT CONNECT-348 Percutaneous Left Ventricular Assist Device Bridge to Successful Percutaneous Mitral Valve Edge-to-Edge Repair in Patients With Severe Mitral Regurgitation and Acute Cardiogenic Shock
Authors: Divya Ratan Verma, Hursh Naik, Timothy Byrne, Satya Reddy Atmakuri, Samuel Unzek, Ligita Centorino, Orazio Amabile, George Gellert, Samuel Butman, David Biglari, Kenith Fang, Thomas Waggoner, Radha Gopalan
Journal: Journal of the American College of Cardiology (2020)
TCT CONNECT-104 Incidence and Predictors of 6-Month Readmission for Acute Myocardial Infarction After Transcatheter Aortic Valve Replacement in the United States
Authors: Syed Zaid, Aaqib Malik, Joshua Goldberg, Cenap Undemir, Steven Lansman, Hasan Ahmad, Gilbert Tang
Journal: Journal of the American College of Cardiology (2020)
COVID-19 update: The race to therapeutic development
Authors: Julianne D. Twomey, Shen Luo, Alexis Q. Dean, William P. Bozza, Ancy Nalli, Baolin Zhang
Journal: Drug Resistance Updates (2020)

The COVID-19 pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), represents an unprecedented challenge to global public health. At the time of this review, COVID-19 has been diagnosed in over 40 million cases and associated with 1.1 million deaths worldwide. Current management strategies for COVID-19 are largely supportive, and while there are more than 2000 interventional clinical trials registered with the U.S. National Library of Medicine (clinicaltrials.gov), results that can clarify benefits and risks of candidate therapies are only gradually becoming available. We herein describe recent advances in understanding SARS-CoV-2 pathobiology and potential therapeutic targets that are involved in viral entry into host cells, viral spread in the body, and the subsequent COVID-19 progression. We highlight two major lines of therapeutic strategies for COVID-19 treatment: 1) repurposing the existing drugs for use in COVID-19 patients, such as antiviral medications (e.g., remdesivir) and immunomodulators (e.g., dexamethasone) which were previously approved for other disease conditions, and 2) novel biological products that are designed to target specific molecules that are involved in SARS-CoV-2 viral entry, including neutralizing antibodies against the spike protein of SARS-CoV-2, such as REGN-COV2 (an antibody cocktail), as well as recombinant human soluble ACE2 protein to counteract SARS-CoV-2 binding to the transmembrane ACE2 receptor in target cells. Finally, we discuss potential drug resistance mechanisms and provide thoughts regarding clinical trial design to address the diversity in COVID-19 clinical manifestation. Of note, preventive vaccines, cell and gene therapies are not within the scope of the current review.
Energy Flow Through Marine Ecosystems: Confronting Transfer Efficiency
Authors: Tyler D. Eddy, Joey R. Bernhardt, Julia L. Blanchard, William W.L. Cheung, Mathieu Colléter, Hubert du Pontavice, Elizabeth A. Fulton, Didier Gascuel, Kelly A. Kearney, Colleen M. Petrik, Tilla Roy, Ryan R. Rykaczewski, Rebecca Selden, Charles A. Stock, Colette C.C. Wabnitz, Reg A. Watson
Journal: Trends in Ecology & Evolution (2020)
Checking the Hippo in Sarcomatoid Renal Cell Carcinoma with Immunotherapy
Authors: Joyce K. Hwang, Neeraj Agarwal, James Brugarolas, Tian Zhang
Journal: Clinical Cancer Research (2020)

Subset analysis of patients with sarcomatoid renal cell carcinoma (sRCC) included in the CheckMate 214 trial of ipilimumab-nivolumab versus sunitinib showed improved outcomes in sRCC with ipilimumab-nivolumab. The use of checkpoint inhibitor-based regimens in sRCC, for which therapeutic options were once limited, is further supported by additional clinical trials.See related article by Tannir et al., p. 78.
Characterization of Myocardial Injury in Patients With COVID-19
Authors: Gennaro Giustino, Lori B. Croft, Giulio G. Stefanini, Renato Bragato, Jeffrey J. Silbiger, Marco Vicenzi, Tatyana Danilov, Nina Kukar, Nada Shaban, Annapoorna Kini, Anton Camaj, Solomon W. Bienstock, Eman R. Rashed, Karishma Rahman, Connor P. Oates, Samantha Buckley, Lindsay S. Elbaum, Derya Arkonac, Ryan Fiter, Ranbir Singh, Emily Li, Victor Razuk, Sam E. Robinson, Michael Miller, Benjamin Bier, Valeria Donghi, Marco Pisaniello, Riccardo Mantovani, Giuseppe Pinto, Irene Rota, Sara Baggio, Mauro Chiarito, Fabio Fazzari, Ignazio Cusmano, Mirko Curzi, Richard Ro, Waqas Malick, Mazullah Kamran, Roopa Kohli-Seth, Adel M. Bassily-Marcus, Eric Neibart, Gregory Serrao, Gila Perk, Donna Mancini, Vivek Y. Reddy, Sean P. Pinney, George Dangas, Francesco Blasi, Samin K. Sharma, Roxana Mehran, Gianluigi Condorelli, Gregg W. Stone, Valentin Fuster, Stamatios Lerakis, Martin E. Goldman
Journal: Journal of the American College of Cardiology (2020)
TCT CONNECT-150 Real World Outcomes With Small (20-mm) Balloon Expandable Sapien 3 Valves Compared to Larger Valves (23-, 26-, and 29-mm)
Authors: Marvin Eng, Amr Abbas, Rebecca Hahn, Dee Dee Wang, Mackram Eleid, William O'Neill
Journal: Journal of the American College of Cardiology (2020)
Concurrent Liver and Mesentery Primary Extraosseous Multiple Myeloma on 18F-FDG PET/CT
Authors: Molly B. Carnahan, Jeremy T. Larsen, Christopher R. Conley, Ming Yang
Journal: Clinical Nuclear Medicine (2020)

Extramedullary multiple myeloma (EMM) is a subset of multiple myeloma with a poor prognosis. We report a rare case with biopsy-proven concurrent liver and mesentery primary EMM at the time of initial staging after serologic diagnosis of multiple myeloma. 18F-FDG PET/CT is valuable in detection of EMM when the patient has no osseous lesions and a negative bone marrow biopsy.
TCT CONNECT-455 Reinterventions After Transcatheter Aortic Valve Replacement With a Supra-Annular Self-Expanding Bioprosthesis
Authors: Kendra Grubb, John Lisko, Daniel O'Hair, William Merhi, John Heiser, Stanley Chetcuti, G. Deeb, Neal Kleiman, Michael Reardon
Journal: Journal of the American College of Cardiology (2020)
TCT CONNECT-456 Determining the Association Between Prosthesis Geometry and Leaflet Thrombosis (LT) Following Transcatheter Aortic Valve Replacement (TAVR)
Authors: Hashrul Rashid, Michael Michail, Abdul Rahman Ihdayhid, Nancy Khav, Sean Tan, Arthur Nasis, James Cameron, Stephen Nicholls, Robert Gooley
Journal: Journal of the American College of Cardiology (2020)
Vitamin D and Calcium Prevent Recurrent Vertigo
Authors: Anita Slomski
Journal: JAMA (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Replication and meta-analyses nominate numerous eosinophilic esophagitis risk genes
Authors: Leah C. Kottyan, Michael P. Trimarchi, Xiaoming Lu, Julie M. Caldwell, Avery Maddox, Sreeja Parameswaran, Michael Lape, Rahul J. D’Mello, Madeline Bonfield, Adina Ballaban, Vincent Mukkada, Philip E. Putnam, Pablo Abonia, Netali Ben-Baruch Morgenstern, Amy A. Eapen, Ting Wen, Matthew T. Weirauch, Marc E. Rothenberg
Journal: Journal of Allergy and Clinical Immunology (2020)
Age-related susceptibility to coronavirus infections: role of impaired and dysregulated host immunity
Authors: Rudragouda Channappanavar, Stanley Perlman
Journal: Journal of Clinical Investigation (2020)

Human coronaviruses (hCoVs) cause severe respiratory illness in the elderly. Age-related impairments in innate immunity and suboptimal virus-specific T cell and antibody responses are believed to cause severe disease upon respiratory virus infections. This phenomenon has recently received increased attention, as elderly patients are at substantially elevated risk for severe COVID-19 disease and experience increased rates of mortality following SARS-CoV-2 infection compared with younger populations. However, the basis for age-related fatal pneumonia following pathogenic hCoVs is not well understood. In this Review, we provide an overview of our current understanding of hCoV-induced fatal pneumonia in the elderly. We describe host immune response to hCoV infections derived from studies of young and aged animal models and discuss the potential role of age-associated increases in sterile inflammation (inflammaging) and virus-induced dysregulated inflammation in causing age-related severe disease. We also highlight the existing gaps in our knowledge about virus replication and host immune responses to hCoV infection in young and aged individuals.
Exogenous Thyroid Hormone Is Associated with Shortened Survival and Upregulation of High-Risk Gene Expression Profiles in Steroid Receptor–Positive Breast Cancers
Authors: Reema S. Wahdan-Alaswad, Susan M. Edgerton, Hiba Salem, Hyun Min Kim, Aik Choon Tan, Jessica Finlay-Schultz, Elizabeth A. Wellberg, Carol A. Sartorius, Britta M. Jacobsen, Bryan R. Haugen, Bolin Liu, Ann D. Thor
Journal: Clinical Cancer Research (2020)

Thyroid disease is a frequent comorbidity in women with breast cancer, and many require thyroid hormone replacement therapy (THRT). We postulated that THRT has a deleterious clinical effect mechanistically through hormonal interactions, nuclear receptor cross-talk, and upregulation of high-risk breast cancer genes.
TCT CONNECT-236 Percutaneous Coronary Intervention of Chronic Total Occlusions Involving a Bifurcation: Insights From the PROGRESS-CTO Registry
Authors: Ilias Nikolakopoulos, Khaldoon Alaswad, James Choi, Jaikirshan Khatri, Robert Yeh, Oleg Krestyaninov, Dmitrii Khelimskii, Farouc Amin Jaffer, Nidal Abi Rafeh, Ahmed ElGuindy, Omer Goktekin, Dimitrios Karmpaliotis, Paul Poomipanit, Evangelia Vemmou, Judit Karacsonyi, Bavana Rangan, Santiago Garcia, Subhash Banerjee, M. Nicholas Burke, Emmanouil Brilakis
Journal: Journal of the American College of Cardiology (2020)
Publisher Correction: Prolonged residence of an albumin–IL-4 fusion protein in secondary lymphoid organs ameliorates experimental autoimmune encephalomyelitis
Authors: Ako Ishihara, Jun Ishihara, Elyse A. Watkins, Andrew C. Tremain, Mindy Nguyen, Ani Solanki, Kiyomitsu Katsumata, Aslan Mansurov, Erica Budina, Aaron T. Alpar, Peyman Hosseinchi, Lea Maillat, Joseph W. Reda, Takahiro Kageyama, Melody A. Swartz, Eiji Yuba, Jeffrey A. Hubbell
Journal: Nature Biomedical Engineering (2020)
2020 ACC Expert Consensus Decision Pathway on Management of Conduction Disturbances in Patients Undergoing Transcatheter Aortic Valve Replacement
Authors: Scott M. Lilly, Abhishek J. Deshmukh, Andrew E. Epstein, Mark J. Ricciardi, Satya Shreenivas, Poonam Velagapudi, Janet F. Wyman
Journal: Journal of the American College of Cardiology (2020)
TCT CONNECT-115 Transcatheter Aortic Valve Replacement for Residual Lesion After “Healed” Infective Endocarditis of the Aortic Valve—Feasibility and Safety Multicenter Study
Authors: Ignacio Amat-Santos, Sandra Santos-Martinez, Luis Nombela-Franco, Francesco Saia, Antonio J. Muñoz-Garcia, Enrique Gutiérrez, Ander Regueiro, Victor Alfonso Jimenez Diaz, Fernando Rivero, Rafael Romaguera
Journal: Journal of the American College of Cardiology (2020)
Efficacy of Tocilizumab in Patients Hospitalized with Covid-19
Authors: John H Stone, Matthew J Frigault, Naomi J Serling-Boyd, Ana D Fernandes, Liam Harvey, Andrea S Foulkes, Nora K Horick, Brian C Healy, Ruta Shah, Ana Maria Bensaci, Ann E Woolley, Sarah Nikiforow, Nina Lin, Manish Sagar, Harry Schrager, David S Huckins, Matthew Axelrod, Michael D Pincus, Jorge Fleisher, Chana A Sacks, Michael Dougan, Crystal M North, Yuan-Di Halvorsen, Tara K Thurber, Zeina Dagher, Allison Scherer, Rachel S Wallwork, Arthur Y Kim, Sara Schoenfeld, Pritha Sen, Tomas G Neilan, Cory A Perugino, Sebastian H Unizony, Deborah S Collier, Mark A Matza, Janeth M Yinh, Kathryn A Bowman, Eric Meyerowitz, Amna Zafar, Zsofia D Drobni, Marcy B Bolster, Minna Kohler, Kristin M D'Silva, Jonathan Dau, Megan M Lockwood, Caroline Cubbison, Brittany N Weber, Michael K Mansour
Journal: New England Journal of Medicine (2020)

The efficacy of interleukin-6 receptor blockade in hospitalized patients with coronavirus disease 2019 (Covid-19) who are not receiving mechanical ventilation is unclear. We performed a randomized, double-blind, placebo-controlled trial involving patients with confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, hyperinflammatory states, and at least two of the following signs: fever (body temperature >38°C), pulmonary infiltrates, or the need for supplemental oxygen in order to maintain an oxygen saturation greater than 92%. Patients were randomly assigned in a 2:1 ratio to receive standard care plus a single dose of either tocilizumab (8 mg per kilogram of body weight) or placebo. The primary outcome was intubation or death, assessed in a time-to-event analysis. The secondary efficacy outcomes were clinical worsening and discontinuation of supplemental oxygen among patients who had been receiving it at baseline, both assessed in time-to-event analyses. We enrolled 243 patients; 141 (58%) were men, and 102 (42%) were women. The median age was 59.8 years (range, 21.7 to 85.4), and 45% of the patients were Hispanic or Latino. The hazard ratio for intubation or death in the tocilizumab group as compared with the placebo group was 0.83 (95% confidence interval [CI], 0.38 to 1.81; P = 0.64), and the hazard ratio for disease worsening was 1.11 (95% CI, 0.59 to 2.10; P = 0.73). At 14 days, 18.0% of the patients in the tocilizumab group and 14.9% of the patients in the placebo group had had worsening of disease. The median time to discontinuation of supplemental oxygen was 5.0 days (95% CI, 3.8 to 7.6) in the tocilizumab group and 4.9 days (95% CI, 3.8 to 7.8) in the placebo group (P = 0.69). At 14 days, 24.6% of the patients in the tocilizumab group and 21.2% of the patients in the placebo group were still receiving supplemental oxygen. Patients who received tocilizumab had fewer serious infections than patients who received placebo. Tocilizumab was not effective for preventing intubation or death in moderately ill hospitalized patients with Covid-19. Some benefit or harm cannot be ruled out, however, because the confidence intervals for efficacy comparisons were wide. (Funded by Genentech; ClinicalTrials.gov number, NCT04356937.).
TCT CONNECT-230 The Impact of Laser Use on the Outcomes of Balloon Uncrossable and Balloon Undilatable Chronic Total Occlusion Percutaneous Coronary Intervention
Authors: Judit Karacsonyi, Khaldoon Alaswad, James Choi, Jaikirshan Khatri, Farouc Amin Jaffer, Paul Poomipanit, Farshad Forouzandeh, Michalis Koutouzis, Ioannis Tsiafoutis, Mitul Patel, Ehtisham Mahmud, Oleg Krestyaninov, Brian Jefferson, Taral Patel, Alpesh Shah, Raj Chandwaney, Jason Wollmuth, Abdul Sheikh, Robert Yeh, Hector Tamez, Wissam Jaber, Habib Samady, Bilal Malik, Srinivasa Potluri, Barry Uretsky, Anthony Doing, Philip Dattilo, Basem Elbarouni, Michael Love, Evangelia Vemmou, Ilias Nikolakopoulos, Iosif Xenogiannis, Bavana Rangan, Santiago Garcia, Imre Ungi, Ahmed ElGuindy, Omer Goktekin, Nidal Abi Rafeh, Emmanouil Brilakis
Journal: Journal of the American College of Cardiology (2020)
Reply to Weatherald <i>et al.</i>: Pulmonary Vascular Resistance in Pulmonary Arterial Hypertension: La Pièce de Résistance?
Authors: Roberto Badagliacca, Michele D’Alto, Stefano Ghio, Carmine Dario Vizza, Robert Naeije
Journal: American Journal of Respiratory and Critical Care Medicine (2020)
Circular RNAs are a novel type of non-coding RNAs in ROS regulation, cardiovascular metabolic inflammations and cancers
Authors: Fatma Saaoud, Charles Drummer I.V., Ying Shao, Yu Sun, Yifan Lu, Keman Xu, Dong Ni, Xiaohua Jiang, Hong Wang, Xiaofeng Yang
Journal: Pharmacology & Therapeutics (2020)
Correction to: Triheptanoin: First Approval
Authors: Matt Shirley
Journal: Drugs (2020)

The article Triheptanoin: First Approval, written by Matt Shirley, was originally published electronically in SpringerLink on 8 September 2020 without open access. After publication in volume 80, issue 15, pages 1595-1600 Ultragenyx Pharmaceutical Inc., requested that the article be Open Choice to make the article an open access publication.
Hard Truths About Suicide Prevention
Authors: Roy H. Perlis, Stephan D. Fihn
Journal: JAMA Network Open (2020)

Nazanin Bahraini, PhD; Lisa A. Brenner, PhD; Catherine Barry, PhD; Trisha Hostetter, MPH; Janelle Keusch, MPH; Edward P. Post, MD, PhD; Chad Kessler, MD; Cliff Smith, PhD; Bridget B. Matarazzo, PsyD